Company: JUNS
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001493152-25-023603
Chunk: 122

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-11-14
Form: 10-Q
Item: Item 1
Chunk 122
---
     81,869  
     117,555 
  
    Accrued
    compensation 
     433,959  
     541,135 
  
    Increase
    in accrued interest 
     3,286  
     110,475 
  
    Net
    cash flows from operating activities 
     (3,045,713) 
     (215,225)

    Cash
    Flows from Financing Activities: 

    Proceeds
    from note payable, related parties 
     -  
     137,000 
  
    Proceeds
    from sale of common stock 
     -  
     50,000 
  
    Net
    cash flows from financing activities 
     -  
     187,000 

    Net
    Change in Cash 
     (3,045,713) 
     (28,225)

    Beginning
    of period 
     3,769,510  
     28,478 
  
    End
    of period 
    $723,797  
    $253 

    Supplemental
    disclosure of cash flow information: 

    Cash
    paid for interest 
    $271  
    $56,891 
  
    Cash
    paid for income taxes 
    $-  
    $- 

    Non-Cash
    Investing and Financing Activities: 

    Restricted
    stock and stock options issued for the forgiveness of accrued compensation 
    $-  
    $60,000 
  
    Notes
    payable, related party assign to Note payable 
    $-  
    $266,667 
  
    Receivables
    from Sale of Common Stock 
    $-  
    $75,000 

The
accompanying notes are an integral part of these condensed consolidated financial statements

7

JUPITER
NEUROSCIENCES, INC.

NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Note
1 – Organization and Description of Business

Jupiter
Neurosciences, Inc. (“JNS,” “we,” “us,” “our,” or the “Company”) is a clinical stage research and development pharmaceutical company located in Jupiter,
Florida. The Company incorporated in Delaware in January 2016. The Company has developed a unique resveratrol platform product primarily
targeting treatment of neuro-inflammation. The product